PL3786160T3 - Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6 - Google Patents

Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6

Info

Publication number
PL3786160T3
PL3786160T3 PL20197194.2T PL20197194T PL3786160T3 PL 3786160 T3 PL3786160 T3 PL 3786160T3 PL 20197194 T PL20197194 T PL 20197194T PL 3786160 T3 PL3786160 T3 PL 3786160T3
Authority
PL
Poland
Prior art keywords
therapeutic uses
pyridine derivatives
trpc6
inhibitors
trpc6 inhibitors
Prior art date
Application number
PL20197194.2T
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Lana Louise Smith Keenan
Michael D. Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3786160T3 publication Critical patent/PL3786160T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL20197194.2T 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6 PL3786160T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
PL3786160T3 true PL3786160T3 (pl) 2022-10-24

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20197194.2T PL3786160T3 (pl) 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6
PL18800513.6T PL3700902T3 (pl) 2017-10-27 2018-10-25 Inhibitory trpc6

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18800513.6T PL3700902T3 (pl) 2017-10-27 2018-10-25 Inhibitory trpc6

Country Status (28)

Country Link
US (4) US10800757B2 (pl)
EP (2) EP3786160B1 (pl)
JP (2) JP7217273B6 (pl)
KR (2) KR20200095467A (pl)
CN (1) CN111527078B (pl)
AU (2) AU2018355743B2 (pl)
BR (1) BR112020007818A2 (pl)
CA (1) CA3078769A1 (pl)
CL (2) CL2020001097A1 (pl)
CY (1) CY1126109T1 (pl)
DK (2) DK3700902T3 (pl)
ES (2) ES2946274T3 (pl)
FI (1) FI3700902T3 (pl)
HR (2) HRP20220991T1 (pl)
HU (2) HUE062460T2 (pl)
IL (2) IL274039B (pl)
LT (2) LT3786160T (pl)
MX (1) MX2020004283A (pl)
PE (1) PE20210154A1 (pl)
PH (1) PH12020550503A1 (pl)
PL (2) PL3786160T3 (pl)
PT (2) PT3700902T (pl)
RS (2) RS63535B1 (pl)
SG (2) SG11202003367TA (pl)
SI (2) SI3700902T1 (pl)
TW (2) TWI780246B (pl)
WO (1) WO2019081637A1 (pl)
ZA (1) ZA202002372B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3700902T1 (sl) * 2017-10-27 2023-10-30 Boehringer Ingelheim International Gmbh Inhibitorji trpc6
US11485740B2 (en) * 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
WO2019161010A1 (en) * 2018-02-16 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
EP3959206A1 (en) * 2019-04-12 2022-03-02 Boehringer Ingelheim International GmbH Inhibitors of trpc6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
US20230137816A1 (en) 2020-02-11 2023-05-04 Deutsches Herzzentrum Muenchen Des Freistaates Bayern Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) * 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
AU2021256963A1 (en) 2020-04-16 2022-09-15 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6 for treating respiratory conditions
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
CA3229735A1 (en) 2021-10-15 2023-04-20 Boehringer Ingelheim International Gmbh Trpc6 inhibitory compounds for treating sepsis
WO2023106421A1 (ja) * 2021-12-06 2023-06-15 国立大学法人熊本大学 Trpc6の発現を抑制する方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JPH06509069A (ja) 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
ATE234270T1 (de) 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
MXPA03011629A (es) 2001-06-15 2004-07-01 Yamanouchi Pharmaceuticals Co Derivado de fenilpiridincarbonilpiperazina.
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
JP2008515972A (ja) 2004-10-13 2008-05-15 ニューロジェン・コーポレーション メラニン濃縮ホルモン受容体のリガンドとしてのアリール置換８−アザビシクロ［３．２．１］オクタン化合物
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
TWI325423B (en) 2005-10-28 2010-06-01 Lilly Co Eli Kinase inhibitors
AU2006331882A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
JP2012512877A (ja) 2008-12-18 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セロトニン５−ｈｔ２ｂ受容体阻害剤
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
KR20120092629A (ko) 2009-10-09 2012-08-21 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
BR112012011823A2 (pt) 2009-11-18 2019-09-24 Novartis Ag métodos e composições para tratar tumores sólidos e outras malignidades
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
WO2011136292A1 (ja) 2010-04-27 2011-11-03 田辺三菱製薬株式会社 新規アミド誘導体およびその医薬としての用途
AU2011253057B2 (en) 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
RU2689421C2 (ru) * 2013-05-27 2019-05-28 Ф.Хоффманн-Ля Рош Аг Новые 3,4-дигидро-2н-изохинолин-1-оны и 2,3-дигидро-изоиндол-1-оны
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
ES2947636T3 (es) 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
WO2017222930A1 (en) 2016-06-20 2017-12-28 Rutgers, The State University Of New Jersey Therapeutic compounds
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
JPWO2018159827A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
US10450303B2 (en) 2017-03-15 2019-10-22 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
SI3700902T1 (sl) 2017-10-27 2023-10-30 Boehringer Ingelheim International Gmbh Inhibitorji trpc6
US11485740B2 (en) 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
WO2019161010A1 (en) 2018-02-16 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6

Also Published As

Publication number Publication date
LT3786160T (lt) 2022-09-26
PT3786160T (pt) 2022-08-19
SG11202003367TA (en) 2020-05-28
SG10202011632RA (en) 2021-01-28
RS63535B1 (sr) 2022-09-30
US20190169168A1 (en) 2019-06-06
HRP20220991T1 (hr) 2022-11-11
CA3078769A1 (en) 2019-05-02
SI3700902T1 (sl) 2023-10-30
DK3786160T3 (da) 2022-08-22
HUE059450T2 (hu) 2022-11-28
EP3786160A1 (en) 2021-03-03
KR20200125758A (ko) 2020-11-04
EP3786160B1 (en) 2022-07-13
JP2021008503A (ja) 2021-01-28
JP7217273B2 (ja) 2023-02-02
LT3700902T (lt) 2023-06-26
ES2924933T3 (es) 2022-10-11
PL3700902T3 (pl) 2023-09-04
CY1126109T1 (el) 2023-11-15
USRE49699E1 (en) 2023-10-17
CN111527078B (zh) 2023-06-02
CN111527078A (zh) 2020-08-11
TW202120494A (zh) 2021-06-01
AU2020250185A1 (en) 2020-11-12
FI3700902T3 (fi) 2023-05-25
EP3700902A1 (en) 2020-09-02
HRP20230502T1 (hr) 2023-09-15
IL274039A (en) 2020-06-30
PH12020550503A1 (en) 2021-03-22
EP3700902B8 (en) 2023-08-02
EP3700902B1 (en) 2023-03-08
CL2020002562A1 (es) 2021-01-15
US20210163449A1 (en) 2021-06-03
AU2018355743B2 (en) 2022-04-14
TW201930294A (zh) 2019-08-01
WO2019081637A1 (en) 2019-05-02
TWI780511B (zh) 2022-10-11
US10889568B2 (en) 2021-01-12
RS64271B1 (sr) 2023-07-31
KR20200095467A (ko) 2020-08-10
CL2020001097A1 (es) 2020-08-28
PE20210154A1 (es) 2021-01-26
US10800757B2 (en) 2020-10-13
SI3786160T1 (sl) 2022-11-30
IL277493A (en) 2020-11-30
BR112020007818A2 (pt) 2020-10-20
ZA202002372B (en) 2023-10-25
ES2946274T3 (es) 2023-07-14
MX2020004283A (es) 2021-10-21
AU2020250185B2 (en) 2022-04-14
JP7217273B6 (ja) 2024-02-08
TWI780246B (zh) 2022-10-11
US20190169167A1 (en) 2019-06-06
JP2021500390A (ja) 2021-01-07
HUE062460T2 (hu) 2023-11-28
JP6979502B2 (ja) 2021-12-15
DK3700902T3 (en) 2023-05-22
IL277493B (en) 2022-02-01
AU2018355743A1 (en) 2020-05-14
IL274039B (en) 2021-08-31
PT3700902T (pt) 2023-05-30

Similar Documents

Publication Publication Date Title
LT3786160T (lt) Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
IL253712B (en) Mysterlein derivatives for coupling and healing
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
IL258978B (en) The use of pyrimidine and pyridine derivatives in the treatment of multiple sclerosis
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
HK1250161B (zh) 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
SI3487851T1 (sl) Derivati aminopiridina in njihova uporaba kot selektivni zaviralci ALK-2
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
IL261645A (en) History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
EP3253734A4 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
IL261644A (en) Oxalyl derivatives and their use as cyclophilin inhibitors
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors